Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Oct;68(4):777–782. doi: 10.1038/bjc.1993.427

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

N Masuda 1, M Fukuoka 1, S Kudoh 1, Y Kusunoki 1, K Matsui 1, N Takifuji 1, K Nakagawa 1, M Tamanoi 1, T Nitta 1, T Hirashima 1, et al.
PMCID: PMC1968602  PMID: 8398707

Abstract

We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this combination. Fourteen previously untreated patients with stage IIIB or IV disease were treated with CPT-11 (90-min intravenous infusion on days 1, 8, and 15) plus cisplatin (60 mg m-2, intravenously on day 1). The starting dose of CPT-11 was 60 mg m-2, and diarrhea was the dose-limiting toxicity at the 90 mg m-2 dose level. All three patients (all four cycles) given 90 mg m-2 of CPT-11 experienced grade 3 diarrhea. Hematologic toxicity was relatively mild. Elimination of CPT-11 was biphasic with a mean (+/- s.d.) beta half-life of 11.36 +/- 7.26 h. The mean terminal half-life of the major metabolite (7-ethyl-10-hydroxycamptothecin; SN-38) was 22.13 +/- 13.28 (s.d.) h, and modest escalation of the CPT-11 dose from 80 mg m-2 to 90 mg m-2 resulted in a statistically significant apparent increase in the plasma concentrations of SN-38. There were one complete response (7%) and five partial responses (36%) among the 14 patients for an overall response rate of 43%. The recommended dose for Phase II studies is 80 mg m-2 of CPT-11 and 60 mg m-2 of cisplatin.

Full text

PDF
779

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16–20. doi: 10.1200/JCO.1992.10.1.16. [DOI] [PubMed] [Google Scholar]
  2. Hertzberg R. P., Caranfa M. J., Hecht S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989 May 30;28(11):4629–4638. doi: 10.1021/bi00437a018. [DOI] [PubMed] [Google Scholar]
  3. Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25;260(27):14873–14878. [PubMed] [Google Scholar]
  4. Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988 Apr 1;48(7):1722–1726. [PubMed] [Google Scholar]
  5. Kaneda N., Nagata H., Furuta T., Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990 Mar 15;50(6):1715–1720. [PubMed] [Google Scholar]
  6. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987 Nov 15;47(22):5944–5947. [PubMed] [Google Scholar]
  7. Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Negoro S., Nishioka M., Nakagawa K., Takada M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992 Aug;10(8):1225–1229. doi: 10.1200/JCO.1992.10.8.1225. [DOI] [PubMed] [Google Scholar]
  8. Masuda N., Fukuoka M., Takada M., Kusunoki Y., Negoro S., Matsui K., Kudoh S., Takifuji N., Nakagawa K., Kishimoto S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol. 1992 Nov;10(11):1775–1780. doi: 10.1200/JCO.1992.10.11.1775. [DOI] [PubMed] [Google Scholar]
  9. Matsuzaki T., Yokokura T., Mutai M., Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol. 1988;21(4):308–312. doi: 10.1007/BF00264196. [DOI] [PubMed] [Google Scholar]
  10. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  11. Negoro S., Fukuoka M., Masuda N., Takada M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Niitani H., Taguchi T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991 Aug 21;83(16):1164–1168. doi: 10.1093/jnci/83.16.1164. [DOI] [PubMed] [Google Scholar]
  12. Ohno R., Okada K., Masaoka T., Kuramoto A., Arima T., Yoshida Y., Ariyoshi H., Ichimaru M., Sakai Y., Oguro M. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990 Nov;8(11):1907–1912. doi: 10.1200/JCO.1990.8.11.1907. [DOI] [PubMed] [Google Scholar]
  13. Tsuji T., Kaneda N., Kado K., Yokokura T., Yoshimoto T., Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn. 1991 Jun;14(6):341–349. doi: 10.1248/bpb1978.14.341. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES